Oculus Innovative Sciences, Inc, una compañía de salud que desarrolla, produce y comercializa una familia de productos basados en la plataforma Microcyn® Technology, que incluye nuevas formulaciones dedicadas a reducir el uso de antibióticos previniendo o tratando infecciones incluyendo aquellas causadas por bacterias y virus, ha confirmado la efectividad de Microcyn® Technology al inactivar la influenza porcina A H1N1. En un test de suspensión de actividad virucidal dependiente del tiempo conducido por un laboratorio independiente, BioScience Laboratories, Inc., la formulación específica de Microcyn® Technology, redujo la infectividad del virus de la influenza porcina en un 99.99% después de solo 30 segundos de exposición.
Oculus está preparando los datos para someterlos a los CDCs y la OMS para ayudar a acelerar el conocimiento global sobre la habilidad de Microcyn® Technology para reducir eficazmente y con seguridad la incidencia de la transmisión de este virus pandémico. Sin embargo, los productos con formulaciones específicas de la Microcyn® Technology no han sido aun revisados o aprobados por ningún organismo regulador para ser indicados en la influenza porcina.

http://www.medicalnewstoday.com/articles/155439.php

We experienced increased consumer use of our Microcyn-based products in April and May when the swine flu first hit in Mexico,” says Sergio Caleti, sales director of Oculus Innovative Sciences of Mexico. “This resulted in an uptick in product sales along with a corresponding increase in market awareness of the Microcyn Technology in Mexico. We are leveraging this increased name recognition with the introduction this year of a family of Mexican consumer products including a new pediatric skin treatment and smaller consumer packaging for the Microcyn-based wound care products.”
Oculus previously announced a humanitarian program in which Microcyn Technology is provided pro bono to organizations that are responding to worldwide healthcare challenges precipitated by natural disaster or epidemic disease. The product will be available according to the regulatory claims in each area and at the request of emergency responders and foundations. Representatives of these groups are encouraged to contact Oculus’ global outreach at go@oculusis.com.

La compañía CEL-SCI anunció que ha presentado una solicitud para la aplicación de una patente provisional en Estados Unidos que cubra sus medicamentos (vacunas) de terapia inmune L.E.A.P.S ™ (Sistema de Presentación del Antígeno por el Epitope del Ligando) para la prevención/tratamiento del H1N1, influenzas aviar y porcina, influenza A y/o mutantes emergentes o variantes de estos virus. Algunos expertos creen que para la próxima estación de influenza los virus de la influenza porcina habrán evolucionado y/o combinado con otros virus para crear un nuevo virus mucho más letal. Esto es lo que pasó en el caso de la pandemia de influenza española. Los esfuerzos de CEL-SCI para combatir el virus están concentrados en el empleo de epitopes conservados de proteínas esenciales que se encuentran en el virus de la influenza A para H1N1, H1N5, influenza porcina y aviar e influenza española para crear un tratamiento/vacuna efectiva que pudiera combatir potencialmente tales virus mutantes.
Geert Kersten, Oficial Ejecutivo Principal del CEL-SCI dijo: “al solicitar esta patente provisional en Estados Unidos estamos preservando nuestros derechos de solicitar patentes sobre estas invenciones y para su uso en todo el mundo tanto como vacuna preventiva antes de que una persona sea infectada o expuesta o como vacuna terapéutica para tratamiento.”

http://www.medicalnewstoday.com/articles/155257.php

Experimental work has been initiated on these various methods of use and applications for the A influenza vaccines. These L.E.A.P.S. vaccines, when used individually or together, are expected to induce antigen specific immune response(s) which, based on other L.E.A.P.S. animal tests in multiple disease models will hopefully lead to a protective immune response.
The most recent such presentation by an outside university investigator (Dr. Borthakur, University of Hawaii) reported new L.E.A.P.S. Tuberculosis data at the Annual American Society for Microbiology in Philadelphia, PA. This TB data demonstrated that vaccines utilizing the L.E.A.P.S. vaccine technology with specificity for particular Mycobacterium tuberculosis (TB) antigens can elicit immune responses that would be expected to be protective against tuberculosis and have the potential to treat swine and other H1N1 influenzas. The TB investigators presented data that showed that blood and spleen cells from immunized mice produced gamma interferon in response to the vaccine, while the cells from mice in the various control groups did not. Other recent L.E.A.P.S. data, presented by Dr. Kenneth S. Rosenthal, Professor of Microbiology, Immunology and Biochemistry at Northeastern Ohio Universities Colleges of Medicine and Pharmacy and colleagues at the 12th NFID meeting in Baltimore showed that CEL-SCI’s L.E.A.P.S. vaccines can activate and cause human blood monocyte cells to become dendritic cells that secrete the IL-12 cytokine. The dendritic cells that result initiate a protective cell mediated and antibody immune response. These results were obtained for L.E.A.P.S. vaccines against herpes simplex and HIV.
The L.E.A.P.S. technology is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been identified, such as infectious, parasitic, malignant or autoimmune diseases and allergies, are potential therapeutic or preventive sites for the application of L.E.A.P.S. technology. Each L.E.A.P.S. construct is composed of a T cell binding ligand (TCBL) which has previously demonstrated the ability to induce and elicit protective immunity and antigen specific antibody production in animal models.
The concept behind the L.E.A.P.S. technology is to directly mimic cell/cell interactions on the dendritic and T-cell surface with synthetic peptides. The L.E.A.P.S. constructs containing the antigenic disease epitope linked to an Immune/T-cell binding ligand (I/TCBL) can be manufactured by peptide synthesis or by covalently linking the two peptides. Depending upon the type of L.E.A.P.S. construct and I/TCBL used, CEL-SCI is able to direct the outcome of the immune response towards the development of T-cell function with primarily effector T-cell functions (T Lymphocyte; helper/effector T lymphocyte, type 1 or 2 [Th1 or Th2], cytotoxic [Tc] or suppressor [Ts]). The L.E.A.P.S. vaccine constructs are chimeric peptides which combine antigen specificity with immune response modulation.
CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R) which is currently being readied for a global Phase III trial. The Company has operations in Vienna, Virginia, and Baltimore, Maryland.